Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors
ConclusionsPatients who received TKI combined with PD-1 inhibitors had a greater risk for HBV reactivation, and those with HBV reactivation had a higher rate of tumor progression and shorter survival time, than those receiving TKI alone.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Infectious Diseases | Liver Cancer